TARRYTOWN, N.Y.--(BUSINESS WIRE)--EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced the results of a new analysis supporting Ceplene’s (histamine dihydrochloride) favorable impact on overall survival and its activity with interleukin-2 (IL-2). Ceplene® is approved in the European Union for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in conjunction with low dose IL-2.
